CAR-T cell therapy is revolutionary in cancer treatment. While producing many remarkable clinical results, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Challenges to effective CAR-T cell therapy include antigen escape, limited tumor infiltration and others.
CAR-T cell therapy also has manufacturing challenges that include high cost of production and long lead times contributing to delays in administering the therapies.
Luminary has developed a platform coupled with a novel set of CARs that address these challenges head on for both hematological malignancy and sold tumors.
